Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases. Endeavor’s lead investigational candidate, taladegib (ENV-101), is an inhibitor of the Hedgehog (Hh) signaling pathway in clinical development for the treatment of fibrotic lung disease, including idiopathic pulmonary fibrosis (IPF).
OUR SCIENCE
Our approach is focused on developing therapies that precisely target the root cause of disease to deliver transformational clinical benefits and the potential to change treatment expectations.
Our leadership team has deep experience developing drug candidates into leading medicines that make a meaningful difference in patients’ lives.
OUR LEADERSHIP
OUR CULTURE
We have a vibrant and passionate culture that reflects our shared mission to deliver new therapeutic options for patients with life-threatening diseases.
LATEST NEWS
Endeavor BioMedicines Announces Publication of Positive Data from Phase 2a Trial in The Lancet Respiratory Medicine Evaluating taladegib (ENV-101) in Individuals with Idiopathic Pulmonary Fibrosis
Treatment with taladegib demonstrated improved lung function from baseline, increased total lung capacity and reversed key measures of lung fibrosis in patients with idiopathic pulmonary fibrosis Data also presented today in ALERT session at European Respiratory Society (ERS) Congress 2025 The between-group difference from baseline to week 12 in percent predicted forced...
Endeavor BioMedicines to Present Results from Phase 2a Trial of Taladegib (ENV-101) in an ALERT Session at European Respiratory Society (ERS) Congress 2025
SAN DIEGO – September 10, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, announced that data from a Phase 2a trial evaluating the safety and efficacy of taladegib (ENV-101) in patients with idiopathic pulmonary fibrosis...
Endeavor BioMedicines Receives Orphan Drug Designation from the U.S. Food and Drug Administration and European Commission for Taladegib (ENV-101) for the Treatment of Idiopathic Pulmonary Fibrosis
SAN DIEGO – July 16, 2025 – Endeavor BioMedicines (“Endeavor”), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced that both the European Commission (EC) and the U.S. Food and Drug Administration (FDA) have granted Orphan Drug...
Fibrotic Lung Disease
Data from a Phase 2a, randomized, double-blind, placebo-controlled 12-week clinical trial suggest Endeavor’s investigational candidate taladegib is the first to show improvement from baseline in lung function combined with evidence it may reverse the course of disease in IPF patients.